Abstract
A novel series of cyclic potent, selective, small molecule, thiol-based inhibitors of activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa) are described. Inhibition of TAFIa with (rac)
2a resulted in dose dependent acceleration of human plasma clot lysis in vitro and was efficacious as an adjunct to tPA in an in vivo rabbit jugular vein thrombolysis model.
A novel series of cyclic potent, selective, small molecule, thiol-based inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa) and the crystal structures of TAFIa inhibitors bound to porcine pancreatic carboxypeptidase B are described. Three series of cyclic arginine and lysine mimetic inhibitors vary significantly in their selectivity against other human basic carboxypeptidases, carboxypeptidase N and carboxypeptidase B. (−)
2a displays TAFIa IC
50
=
3
nM and 600-fold selectivity against CPN. Inhibition of TAFIa with (rac)
2a resulted in dose dependent acceleration of human plasma clot lysis in vitro and was efficacious as an adjunct to tPA in an in vivo rabbit jugular vein thrombolysis model.